Sarissa Capital Management LP continued to hold its position in shares of AbbVie Inc. (NYSE:ABBV) during the first quarter, Holdings Channel reports. The fund owned 10,000 shares of the company’s stock at the end of the first quarter. AbbVie accounts for about 0.3% of Sarissa Capital Management LP’s investment portfolio, making the stock its 10th largest position. Sarissa Capital Management LP’s holdings in AbbVie were worth $651,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ABBV. Norges Bank acquired a new position in shares of AbbVie during the fourth quarter worth about $823,984,000. State Street Corp raised its position in shares of AbbVie by 2.4% in the first quarter. State Street Corp now owns 72,969,530 shares of the company’s stock worth $4,754,696,000 after buying an additional 1,696,042 shares during the period. Wedge Capital Management L L P NC acquired a new position in shares of AbbVie during the first quarter worth about $46,744,000. Orbis Allan Gray Ltd raised its position in shares of AbbVie by 11.8% in the fourth quarter. Orbis Allan Gray Ltd now owns 5,485,407 shares of the company’s stock worth $343,496,000 after buying an additional 579,378 shares during the period. Finally, Legal & General Group Plc raised its position in shares of AbbVie by 4.1% in the first quarter. Legal & General Group Plc now owns 7,918,192 shares of the company’s stock worth $515,956,000 after buying an additional 312,055 shares during the period. Hedge funds and other institutional investors own 67.89% of the company’s stock.

AbbVie Inc. (ABBV) traded up 0.27% on Friday, hitting $70.63. The stock had a trading volume of 3,248,300 shares. The stock’s 50 day moving average is $72.05 and its 200 day moving average is $66.76. AbbVie Inc. has a one year low of $55.06 and a one year high of $75.04. The stock has a market cap of $112.59 billion, a price-to-earnings ratio of 17.37 and a beta of 1.50.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 28th. The company reported $1.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.40 by $0.02. The company had revenue of $6.94 billion for the quarter, compared to analyst estimates of $6.93 billion. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. AbbVie’s revenue was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.26 earnings per share. Analysts anticipate that AbbVie Inc. will post $5.52 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be issued a $0.64 dividend. This represents a $2.56 annualized dividend and a yield of 3.62%. The ex-dividend date is Wednesday, July 12th. AbbVie’s dividend payout ratio (DPR) is 62.90%.

ILLEGAL ACTIVITY WARNING: This story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/08/12/abbvie-inc-nyseabbv-is-sarissa-capital-management-lps-10th-largest-position.html.

A number of research analysts have recently issued reports on ABBV shares. Vetr upgraded AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 target price on the stock in a research report on Monday, May 8th. BMO Capital Markets set a $63.00 target price on AbbVie and gave the company a “hold” rating in a research report on Thursday, April 27th. Credit Suisse Group reiterated a “hold” rating and set a $65.00 target price on shares of AbbVie in a research report on Wednesday, June 7th. Zacks Investment Research lowered AbbVie from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Finally, Deutsche Bank AG increased their target price on AbbVie from $64.00 to $65.00 and gave the company a “hold” rating in a research report on Friday, April 28th. Nine equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $74.66.

In other news, CEO Richard A. Gonzalez sold 65,861 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $71.00, for a total value of $4,676,131.00. Following the sale, the chief executive officer now directly owns 342,353 shares in the company, valued at $24,307,063. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Richard A. Gonzalez sold 193,131 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $71.00, for a total value of $13,712,301.00. Following the completion of the sale, the chairman now owns 469,623 shares in the company, valued at $33,343,233. The disclosure for this sale can be found here. Insiders sold 600,026 shares of company stock worth $41,852,724 in the last three months. 0.23% of the stock is owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.